BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Innorna Secures FDA Clearance For First In Class mRNA Therapy IN026 In Refractory Gout

IN026 is a potential first-in-class mRNA therapy for refractory gout, marking the emergence of a new category of mRNA medicines enabled by Innorna's propri...

March 19, 2026 | News

Alphamab Oncology Doses First Patient In Global Phase I Trial Of First PD L1 VEGFR2 Bispecific ADC

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101...

March 18, 2026 | News

Akeso Secures China IND Clearance For First In Class Trispecific Antibody AK150 Targeting Solid Tumours

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has rec...

March 17, 2026 | News

Hong Kong Approves Ohtuvayre For COPD Maintenance Treatment Under 1 Plus Regulatory Pathway

Approval marks the second regulatory approval outside of the U.S. Food and Drug Administration, further expanding access to COPD patients in select Special...

March 16, 2026 | News

Alphamab Oncology IND For Dual Payload Bispecific ADC JSKN021 Accepted By China NMPA

Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative du...

March 16, 2026 | News

Codex Genetics And C2N Diagnostics Partner To Expand Alzheimer’s Blood Test Access In Hong Kong

Codex Genetics, a leading precision diagnostics company headquartered in Hong Kong, today announces a strategic collaboration with C2N Diagnostics (C2N), a...

March 11, 2026 | News

Ascletis Reports Positive Phase II Results For Monthly ASC30 Injection In Obesity Treatment

- ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of ...

March 11, 2026 | News

Akeso Reports Durable Long Term Survival Benefit Of Cadonilimab In Advanced Cervical Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the latest long-term survival analysis data from the China pivotal registrational Phase II ...

March 06, 2026 | Report

Hua Medicine Secures First Glucokinase Activator Approval Outside Mainland China In Hong Kong

First glucokinase-activator (GKA) approval outside mainland China Approval supports a differentiated approach to Type 2 diabetes (T2D) ma...

March 04, 2026 | News

Antengene And Junshi Biosciences Enter Clinical Collaboration To Advance ATG 037 And JS207 Combination In Solid Tumors

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, ...

February 26, 2026 | News

Omics Empower Expands Spatial Transcriptomics Services With Xenium Platform In Hong Kong

Omics Empower, a global life science service provider specializing in single-cell sequencing and spatial transcriptomics, announced that Xenium™ In S...

February 16, 2026 | News

Ascletis Advances ASC36 Oral Amylin Tablet With Strong Preclinical Weight Loss Data

Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady...

February 12, 2026 | News

Everest Medicines Secures Exclusive Asia Pacific Rights To First In Class Dual Target SHPT Therapy MT1013

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturi...

February 06, 2026 | News

Akso Health Group Launches Exploratory Global Patient Support Programme With Nanning Duoling Research Institute To Expand Zero Cost Cancer Care Access

Akso Health Group (NASDAQ: AHG) ("Akso Health" or the "Company") announced the launch of the an exploratory patient support program and a strategic coopera...

February 05, 2026 | News

Stay Connected